Building a Pipeline of Novel Drugs
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs. Currently we have three candidates in clinical development and several molecules in preclinical development
- PCI-32765, first-in-human, oral therapy that is a selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor being investigated in B-cell hematologic malignancies.
- PCI-27483, a subcutaneously administered Factor VIIa inhibitor targeting tissue factor expressing tumors in oncology (being investigated in pancreatic cancer).
- PCI-24781, abexinostat hydrochloride, an oral Histone Deacetylase (HDAC) inhibitor being investigated in oncology applications, such as lymphomas and solid tumor malignancies.
- BTK Inhibitor compounds for autoimmune diseases in preclinical development
- Isoform selective HDAC8 inhibitors in preclinical development
